{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:12:12Z","timestamp":1789809132841,"version":"4.0.1"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Osteosarcoma is the most common bone malignancy in children. We describe the survival outcomes of children diagnosed with osteosarcoma at a tertiary care cancer centre in Pakistan treated with a methotrexate-based treatment regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This was a retrospective review of electronic medical records at our institute for patients diagnosed with osteosarcoma between January 1st, 2011, to December 31st, 2020. Kaplan Meier curves were generated. Overall survival (OS) was defined as the time from diagnosis to death or last follow up. Event-free survival (EFS) was defined as time from diagnosis to death, progression, relapse, treatment abandonment, or last follow up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 372 medical charts, of which 35 were excluded (34 abandoned prior to therapy, 1 chondrosarcoma), leaving 337 records for analysis. Median age was 13.8 years (range 2.4 \u2013 17.9 years). At baseline, 295 patients (87.5%) had localized disease, and the lower extremity was the most common primary tumour site (286, 84.9%). The median follow-up time was 55 months (range, 1\u2013149 months), during which 100 deaths were observed (75 attributed to disease progression, 18 infection-related, 7 due to cardiotoxicity), while 42 (12.5%) patients abandoned active treatment. The median overall survival was not reached. The estimated 3-year, 5-year, and 10-year overall survival rates with 95% confidence intervals were 72% (67 \u2013 78%), 65% (59 \u2013 71%), and 55% (44 \u2013 69%), respectively. The median EFS was 26.6 months. The estimated 3-year, 5-year, and 10-year EFS rates with 95% CI were 43% (39 \u2013 49%), 40% (35 \u2013 46%), and 25% (16 \u2013 40%), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Survival outcomes for localized osteosarcoma with a methotrexate-based treatment regimen are near regional estimates but reflect a high rate of infection-related mortality, treatment abandonment, and amputations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/jcas-2026-0018","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:31:25Z","timestamp":1789806685000},"page":"114-121","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Methotrexate-Based Therapy for Paediatric Osteosarcoma: A Decade of Experience from a Cancer Centre in Pakistan"],"prefix":"10.2478","volume":"12","author":[{"given":"Duraksh","family":"Arshad","sequence":"first","affiliation":[{"name":"Department of Paediatric Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Osama","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleema","family":"Saeed","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilyas","family":"Rafi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Pathology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Sarfraz","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfana Ishaq","family":"Sindhu","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Sadaf","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"2026091908311952616_j_jcas-2026-0018_ref_001","doi-asserted-by":"crossref","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","DOI":"10.3322\/caac.21871"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_002","doi-asserted-by":"crossref","unstructured":"Eaton BR, Schwarz R, Vatner R, Yeh B, Claude L, Indelicato DJ, et al. Osteosarcoma. Pediatric Blood & Cancer. 2021;68(S2):e28352.","DOI":"10.1002\/pbc.28355"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_003","doi-asserted-by":"crossref","unstructured":"Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol. 2015;33(20):2279\u201387.","DOI":"10.1200\/JCO.2014.60.0734"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_004","unstructured":"Bhurgri Y, Usman A, Bhurgri H, Faridi N, Bashir I, Bhurgri A, et al. Primary malignancies of bone and cartilage in Karachi. Asian Pac J Cancer Prev. 2009;10(5):891\u20134."},{"key":"2026091908311952616_j_jcas-2026-0018_ref_005","doi-asserted-by":"crossref","unstructured":"Mailankody S, Kumar VS, Khan SA, Banavali SD, Bajpai J. Resource-appropriate selection of osteosarcoma treatment protocols in low- and middle-income countries. Pediatr Blood Cancer. 2022;69(3):e29540.","DOI":"10.1002\/pbc.29540"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_006","doi-asserted-by":"crossref","unstructured":"Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26(2):407\u201314.","DOI":"10.1093\/annonc\/mdu526"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_007","doi-asserted-by":"crossref","unstructured":"Mostert S, Arora RS, Arreola M, Bagai P, Friedrich P, Gupta S, et al. Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group. Lancet Oncol. 2011;12(8):719\u201320.","DOI":"10.1016\/S1470-2045(11)70128-0"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_008","doi-asserted-by":"crossref","unstructured":"Ariello K, Hadi AN, Denburg A, Gupta S. Survival Outcomes for Adolescent and Young Adults With Cancer in Low- and Middle-Income Countries: A Systematic Review. JCO Glob Oncol. 2025;11:e2400326.","DOI":"10.1200\/GO-24-00326"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_009","doi-asserted-by":"crossref","unstructured":"Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36\u201350.","DOI":"10.1016\/j.ejca.2018.11.027"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_010","doi-asserted-by":"crossref","unstructured":"Yasin NF, Abdul Rashid ML, Ajit Singh V. Survival analysis of osteosarcoma patients: A 15-year experience. J Orthop Surg (Hong Kong). 2020;28(1):2309499019896662.","DOI":"10.1177\/2309499019896662"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_011","doi-asserted-by":"crossref","unstructured":"Bajpai J, Chandrasekharan A, Talreja V, Simha V, Chandrakanth MV, Rekhi B, et al. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen \u2018OGS-12\u2019. Eur J Cancer. 2017;85:49\u201358.","DOI":"10.1016\/j.ejca.2017.08.013"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_012","doi-asserted-by":"crossref","unstructured":"Choeyprasert W, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, Anurathapan U, et al. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. Asian Pac J Cancer Prev. 2014;15(22):9823\u20139.","DOI":"10.7314\/APJCP.2014.15.22.9823"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_013","doi-asserted-by":"crossref","unstructured":"Shah SC, Kayamba V, Peek RM, Heimburger D. Cancer Control in Low- and Middle-Income Countries: Is It Time to Consider Screening? J Glob Oncol. 2019;5:1\u20138.","DOI":"10.1200\/JGO.18.00200"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_014","doi-asserted-by":"crossref","unstructured":"Xin S, Wei G. Prognostic factors in osteosarcoma: A study level meta-analysis and systematic review of current practice. J Bone Oncol. 2020;21:100281.","DOI":"10.1016\/j.jbo.2020.100281"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_015","doi-asserted-by":"crossref","unstructured":"Guedes A, Nakagawa SA. Biopsy of bone tumors: a literature review. Rev Assoc Med Bras (1992). 2024;70(suppl 1):e2024S131.","DOI":"10.1590\/1806-9282.2024s131"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_016","doi-asserted-by":"crossref","unstructured":"Hamed Kassem Abdelaal A, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Tsuchiya H. Epiphyseal Sparing and Reconstruction by Frozen Bone Autograft after Malignant Bone Tumor Resection in Children. Sarcoma. 2015;2015:892141.","DOI":"10.1155\/2015\/892141"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_017","doi-asserted-by":"crossref","unstructured":"Ehrlich BS, McNeil MJ, Pham LTD, Chen Y, Rivera J, Acuna C, et al. Treatment-related mortality in children with cancer in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Oncol. 2023;24(9):967\u201377.","DOI":"10.1016\/S1470-2045(23)00318-2"},{"key":"2026091908311952616_j_jcas-2026-0018_ref_018","doi-asserted-by":"crossref","unstructured":"Schwartz CL, Wexler LH, Krailo MD, Teot LA, Devidas M, Steinherz LJ, et al. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2016;63(1):54\u201361.","DOI":"10.1002\/pbc.25753"}],"container-title":["Journal of Cancer and Allied Specialties"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/jcas-2026-0018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:31:32Z","timestamp":1789806692000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/jcas-2026-0018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,9,10]]},"published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.2478\/jcas-2026-0018"],"URL":"https:\/\/doi.org\/10.2478\/jcas-2026-0018","relation":{},"ISSN":["2411-989X"],"issn-type":[{"value":"2411-989X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}